Skip to main content

Together we are beating cancer

Donate now
  • Personal Stories

“There really is hope after cancer”: Four people share their experience of lung cancer

Sophie Wedekind
by Sophie Wedekind | Personal stories

29 November 2024

0 comments 0 comments

Eileen smiling on a park bench
Eileen

Lung cancer is the third most common cancer in the UK, accounting for 13% of all new cancer cases. It’s unfortunately also the most common cause of cancer death.

For lung cancer awareness month, we’re sharing the driving progress our research is making, thanks to our supporters, for people affected by the disease.

Here, four people who have experienced lung cancer share their stories.

Susie’s story

Susie smiling
Susie

“Until five years before my diagnosis I smoked 10 to 12 cigarettes a day because when I was a teenager everyone else was doing it and there were no health warnings. By the time there were, I was hooked.”

In 2017 Susie developed a cough which wouldn’t go away. She visited her GP, and when it still hadn’t gone away a few weeks later, she was referred for an X-ray.

“After that, everything happened very quickly. I was immediately called back to the GP and told I would need to be referred to a specialist.

“I had an appointment within a couple of days, and all kinds of scans, and was diagnosed with lung cancer. It was not a shock, as I had been a smoker for 30 years and realised with the speed of my referral to a specialist centre and all the tests that something must be wrong.”

In June 2017 Susie had surgery to remove the bottom lobe of her right lung and some of her lymph nodes.

She then had immunotherapy and chemotherapy – pembrolizumab with cisplatin – and radiotherapy. When her treatment was over, her scans showed no signs of cancer.

“In June, when I was diagnosed, I was asked if I would join the TRACERx study funded by Cancer Research UK to look at the make-up of non-small cell lung cancer and how it changes over time with a view to developing better treatments. I was followed up every six months at the time of my usual follow-up with the consultant until my last appointment in July 2022. I had scans and blood was taken, the organisers also received cancer tissue from my surgery to analyse.”

What is TRACERx?

Susie took part in TRACERx, our flagship lung cancer study. It’s one of our largest studies, involving 19 centres across the UK, 250 researchers and clinicians, and over 800 people with non-small cell lung cancer.

TRACERx has helped to provide evidence for how air pollution can cause lung cancer, unravelled the secrets of how lung cancer can evolve, spread and resist treatment and demonstrated how blood tests can be used to track lung cancer.

And we’re not done yet. In 2022, we funded, which aims to bring a deeper biological understanding of lung cancer evolution, prevention, diagnosis and treatment to the clinic.

Warren’s story

Warren is an avid runner, has never smoked and is generally fit and healthy, so he thought nothing of it when he developed a cough in 2021 that came and went.

Warren smiling in his cabin crew uniform, before his diagnosis
Warren

“As this was the time of Covid-19, I had to test regularly in my job as cabin crew, and the tests always came back negative.

“Although I wasn’t coughing up blood or anything and had no other symptoms of illness, I did go to see my GP in June 2021, who wasn’t overly concerned. I was prescribed antihistamines, which didn’t make any difference, and then omeprazole when I went back, as it was then thought the problem might be acid reflux.”

Eventually, Warren received a chest X-ray and, as a follow up from his radiologist, he was also sent for a CT scan.

After several more tests he still didn’t have a diagnosis, but his consultant had spotted something in his lung that would need to be removed with surgery.

“It was not the greatest Christmas knowing I was facing lung surgery the following month, but at the same time I was glad to be getting out whatever was there. I was told I would not lose much of my lung function and there was no sign of any spread, which was the outcome I was hoping for.”

Warren had surgery to remove part of his left lung on 21 January.

Warren in a hospital bed with a breathing tube in his mouth
Warren, during his treatment

“Despite the length and complexity of the surgery, I was discharged from hospital the following day and, in February 2022, finally got a diagnosis of Stage 3a lung cancer. Some of my lymph nodes had been taken out during the surgery, and cancer was found in two of them.”

Warren’s surgery was followed up with four cycles of chemotherapy.

“The first cycle was carboplatin with vinorelbine, but I asked if the carboplatin could be replaced with cisplatin, having read up on the drugs, even though it was a harsher regime.

“While the first cycle passed without incident, I developed horrendous side effects from the second cycle onwards. My hair thinned out completely and I had fatigue and nausea, although they were well controlled with medication, and my team did all they could to help me – the quality of my care was excellent.”

Scans in May showed that the chemotherapy was working and Warren had four weeks of radiotherapy in August.

In January 2023, following four-monthly scans which were all clear, Warren was signed off as fit to fly again so that he could return to work. He’s been back working on long-haul flights and running 15-20 miles a week since.

“Although I am living my best life again, I am planning to start counselling to help me cope with the anxiety over whether my cancer will come back, as I have been agitating at every little sign of illness. I am also planning to do some fundraising runs for Cancer Research UK and other charities like the Roy Castle Trust.”

Eileen’s story

Eileen smiling in a park with her husband and daughter
Eileen with her husband and daughter

In 2016, Eileen was diagnosed with lung cancer for the first time.

She had given up smoking six years prior and had been to see her GP about some lung issues she was having and was referred for some follow up tests.

During a holiday in Guatemala, Eileen noticed she was finding it difficult to breathe. She put it down the altitude, but decided that when she returned, she would go back to see her GP and was referred for an X-ray.

“I feel lucky it was picked up when it was. At the time I didn’t realise that I had any symptoms although looking back I probably did.”

Eileen had surgery to have part of her lung removed. And when she was in hospital she was approached by a nurse who asked if she would be willing to take part in the TRACERx study.

Eileen smiling on a park bench
Eileen

“The study involved being followed up and giving blood samples which I was very happy to do. It was nice to think my having cancer could be of use. And I wanted to have the last word – not the cancer.”

However, the cancer returned  and spread to Eileen’s brain. But there was hope. Eileen was offered an immunotherapy drug, atezolizumab, which hadn’t yet been approved for use. She had 16 sessions of immunotherapy and after the first session it was clear that it was working.

She was able to complete the course with no side effects and 18 months later the immunotherapy was approved for use.

Since then, Eileen continues to have regular check-ups every six months.

“Hopefully research will help to find a cure one day, but it might also help to develop quicker and kinder treatments too. New treatments are also giving people more time and a better quality of life as well.”

Jennifer’s story

“I found out I had cancer by accident. In 2012 I was diagnosed with pneumonia, strangely enough on a beautiful day in May, and in March 2013 the latest of several follow-up X-rays showed what the doctor thought was an abscess on my left lung.”

After several more tests and investigations, in July 2013 Jennifer was told she had stage 2b lung cancer.

At only 39, and with no history of smoking, this was a huge shock to Jennifer.

Jenny smiling
Jennifer

Initially, Jennifer’s treatment was chemotherapy – cisplatin and docetaxel.

“The side effects were severe – I had terrible mouth ulcers, found it very difficult to eat and lost two stone. My hair started falling out after the second treatment and I was extremely fatigued. I had to give up my job, and it was a year before I was well enough to work again.”

Jennifer’s chemotherapy finished in September 2013, and in November of that year her left lung was removed.

“There were no complications, but I was left very breathless as I struggled to get used to managing with just one lung. At its worst it would take me 10 minutes to be able to get up in the morning, but eventually I was fit enough to hold down my new and current job as a catering assistant.

“Life has been better since I was told in December 2013 that I was cancer free.  Getting married has always been one of my dreams, but in March 2016 it became a reality.  Andrew and I have been together since 2001, and he was extremely supportive during my illness; I think he was more emotionally overcome than I was when we finally got married.

“Now the future looks bright, and I feel extremely lucky to have been given a second chance at life. There really is hope after cancer.”

Our involvement in carboplatin and cisplatin

We were a key player in the development of many drugs that are used to treat lung cancer, including carboplatin and cisplatin.

These platinum-based drugs have had a huge impact since their discovery and are still used to treat a wide range of cancers including lung, breast, bladder, cervical and ovarian.

Drugs linked to Cancer Research UK’s research are used to treat more than 13,500 people with lung cancer in the UK every year. This means more than 8 in 10 lung cancer patients prescribed cancer drugs receive at least one drug that Cancer Research UK has helped to develop.*

The road ahead

Through our research and campaigning in lung cancer prevention, early diagnosis and treatment, we’ve helped to avoid nearly 668,000 UK lung cancer deaths**. But we still have a long way to go. That’s why, right now, we’re tackling lung cancer head on through our research and policy work.

 


 

*Estimated based on CRUK analysis of England data.

**Calculated by the Cancer Intelligence Team at Cancer Research UK, September 2024. Lung cancer (ICD-10 C33-C34) deaths avoided is calculated by subtracting the number of observed lung cancer deaths from the number of expected lung cancer deaths. Expected lung cancer deaths is calculated by applying age- and sex-specific lung cancer mortality rates from the year in which age- and nation-specific lung cancer age-standardised mortality rates peaked, to corresponding population figures.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.